COMPANY

Imvax

HQ: Philadelphia, PA source · imvax.com ↗ · Mid-Atlantic

Keywords: oncology solid tumors Glioblastoma

Location: Philadelphia, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Undisclosed round · $29M · announced Jan 29, 2025 Company release ↗
Source quote
- Jan 29, 2025 · Company release ↗
  “— Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the closing of a $29 million financing round from existing investors”

Raises announced in these releases: $29M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Jan 29, 2025 Raise Private equity round: $29M (total, as published), announced Jan 29, 2025. Source: company's own press page. source ↗
Jan 29, 2025 Raise Undisclosed round · $29M source ↗
Mar 20, 2023 Trial start 2: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma source ↗

2027-01 (ESTIMATED) · 2 · A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma · NCT04485949

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $29.0M. Last 2 years.

Jan 29, 2025 Private equity round: $29M (total, as published), announced Jan 29, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT04485949	A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma	2	Active, not recruiting	Mar 20, 2023	2027-01 (estimated)